Navigation Links
Inspiration Biopharmaceuticals' OBI-1 Receives Orphan Drug Designation in Europe
Date:10/19/2010

LAGUNA NIGUEL, Calif., Oct. 19 /PRNewswire/ -- Inspiration Biopharmaceuticals, Inc. (Inspiration) announced today that the European Commission has granted orphan drug status for OBI-1 for the treatment of hemophilia.  Expected to enter pivotal clinical trials before the end of this year, OBI-1 is designed to treat individuals with hemophilia who have developed inhibitors against human Factor VIII (hFVIII).  The orphan drug status would trigger a 10-year market exclusivity for OBI-1 in the European Union after its marketing approval.  The U.S. Food & Drug Administration (FDA) issued an Orphan Drug Designation for OBI-1 in March 2004.

Michael Griffith, Ph.D., President and CEO of Inspiration, commented, "OBI-1 provides a unique, alternative approach to treating individuals with hemophilia who develop an immune reaction to human FVIII.  The orphan drug designation in Europe is another sign of the overall progress of our program to develop OBI-1 and address a clear, unmet medical need among individuals with hemophilia."  According to a partnership agreement signed with Ipsen SA (Euronext: IPN; ADR: IPSEY) in January 2010, Inspiration licensed OBI-1 from Ipsen and is responsible for the OBI-1 clinical trial development and commercialization.

About Hemophilia

Hemophilia is a bleeding disorder caused by low levels or absence of a protein called a coagulation factor, essential for blood clotting.  The two most common forms of hemophilia are types A and B.  Hemophilia A is caused by a factor VIII deficiency and occurs in ~1 out of every 5,000 male births.  Hemophilia B is caused by factor IX deficiency and occurs in ~1 out of every 30,000 male births.  Approximately 60% of persons with hemophilia have a severe condition, which results in frequent spontaneous bleeding episodes in addition to serious bleeding after injuries.  The annual market for hemophilia treatments is $7.5 billion worldwide.

About OBI-1

Approximately one-third of individuals with hemophilia A develop an immune reaction (inhibitors) to hFVIII and can no longer respond to treatment with the coagulation factor.  Current therapies, specifically FVIIa and FEIBA, work by bypassing the natural hemostatic pathway and forcing coagulation with much higher levels of FVIIa than normal.  In contrast, OBI-1, a recombinant form of porcine FVIII that typically possesses low cross reactivity to anti-hFVIII antibodies, is a replacement therapy, activating the natural hemostatic pathway.  This would allow clinicians to correlate activity and efficacy with a biomarker and therefore guide dosing and better predict treatment outcomes.  OBI-1 presents a unique and alternative approach to address the needs of individuals who have developed inhibitors to FVIII and is highly desired by the medical and patient communities.

OBI-1 has been evaluated in a Phase 2 study in patients with congenital hemophilia A who have developed inhibitors to FVIII and who presented with a non life/non limb threatening bleed.  The Phase 2 study demonstrated OBI-1 was well-tolerated and can be given over a short infusion time.  Inspiration expects to initiate a pivotal trial of OBI-1 in individuals with acquired hemophilia in the fourth quarter of 2010 and a separate pivotal trial in individuals with congenital hemophilia who have developed inhibitors against hFVIII in the first half of 2011.

About Inspiration Biopharmaceuticals

Inspiration Biopharmaceuticals is dedicated exclusively to developing treatments for hemophilia, with a primary mission to broaden access to care, including prophylactic therapy, and improve the treatment of individuals with inhibitor complications.  Inspiration has a broad development portfolio, which includes advanced, clinical-stage product candidates for the treatment of hemophilia A and hemophilia B.

Inspiration's lead product candidates are IB1001, an intravenous recombinant factor IX (FIX) for the acute and preventative treatment of bleeding in individuals with hemophilia B, and OBI-1, an intravenous porcine recombinant factor VIII (FVIII) for the treatment of individuals who have developed inhibitors against human FVIII and for individuals with acquired hemophilia A.  IB1001 currently is in Phase 3 clinical development, and OBI-1 is expected to begin the first of two pivotal trials later this year.  Earlier-stage preclinical programs at Inspiration are focused on human recombinant factor VIIa (FVIIa) for individuals with either hemophilia A or hemophilia B who have developed inhibitors and individuals with factor VII deficiency, and human recombinant FVIII to treat individuals with hemophilia A.

Inspiration's team has extensive expertise and background in hemophilia product development, biologics manufacturing, regulatory approval and global commercialization; the Company's senior leadership was directly responsible for the development and commercialization of the majority of hemophilia products currently on the market.  In addition, in January 2010, Inspiration entered into a strategic partnership with Ipsen SA, leveraging the combined expertise and resources of the two companies.  For further information on Inspiration, please visit http://www.inspirationbio.com.


'/>"/>
SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. National Expressions of Courage Art Contest Unveils Stories of Inspiration
2. Inspiration for My Sisters Keeper Speaks Out
3. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
4. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
5. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
7. FierceBiotech Designates Alder Biopharmaceuticals One of Top Private Biotechs, Member of the 2010 Fierce 15
8. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
9. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
11. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- In the first ever attempt to include phytocannabinoids ... C. sativa, the Hebrew University in Jerusalem, the University ... , the Universita` del Piemonte Orientale and Phytoplant Research ... unified inventory of phytocannabinoids of different botanical origin. ... chemical and structural diversity of phytocannabinoids. As a result ...
(Date:12/2/2016)... Dec. 2, 2016  Maxor National Pharmacy Services, LLC ("Maxor"), ... Specialties, Inc. ("PSI").  The combination of Texas ... -based PSI bring together both company,s clinical expertise and ... payers an industry-leading specialty pharmacy. About Maxor ... , , ...
(Date:12/2/2016)... , December 2, 2016 Orthopedic ... & Support) is Expected to Gain a Significant Market Share ... Orthopedic Ailments  ... , According to a ... on Medical Implants Sterile Packaging: Clamshell Product Type Segment Projected ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass ... will help provide scholarship funds for area students and operating support to UNCF-member ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... CA (PRWEB) , ... December 02, 2016 , ... ... surgeon in Beverly Hills, California, will be included in the 2016 “Guide to ... to exceptional professionals based on the amalgamation of their education, experience, and professional ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... at the Hyatt Regency Waikiki Beach Resort and Spa in Honolulu, offering local ... the field of pain management. , The demand for supplemental training related ...
(Date:12/2/2016)... ... December 02, 2016 , ... Yisrayl Hawkins, at The House ... this current generation fits into Bible Prophecy. Yisrayl says this generation, known as the ... this conclusion, showing how the details line up exactly with Bible Prophecy – a ...
Breaking Medicine News(10 mins):